• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Clearside inks clinical development deal with EyeKor

March 31, 2017 By Sarah Faulkner

Clearside inks clinical development deal with EyeKorClearside Biomedical (NSDQ:CLSD) said today that it landed a deal with EyeKor Inc. to support its clinical trials. The companies did not disclose any financial details of the agreement.

Clearside is conducting a Phase III trial of suprachoroidally administered CLS-TA, its suspension formulation of triamcinolone acetonide, in patients with macular edema associated with non-infectious uveitis. The company is also evaluating its suprachoroidal CLS-TA, in combination with intravitreally administered Eyelea (aflibercept), in patients with macular edema associated with retinal vein occlusion.

The Alpharetta, Ga.-based company also has a clinical program for diabetic macular edema.

“EyeKor did an outstanding job in our two completed Phase II trials in uveitis and in RVO, and is continuing to support our clinical research programs,” president & CEO Daniel White said in prepared remarks. “The level of service and the prompt and thoughtful nature of their assistance, coupled with the powerful and efficient Excelsior platform, is not just greatly appreciated, but also highly valued.  EyeKor has been a great partner for us and we are looking forward to solidifying our collaboration and to further extending our success in ophthalmology clinical and preclinical programs.”

EyeKor provides image and data management solutions for ophthalmic clinical trials, according to Clearside. According to the deal, Clearside will use EyeKor’s Excelsior cloud-based software platform for clinical and preclinical applications.

The software allows Clearside and its contract research organization partners to manage ocular images and other collected data. Scientists, principal investigators, CRO reps, data managers and reading center graders can all access and track data in real time, Clearside reported.

“We are very pleased to support our partner Clearside, a company solely focused on ophthalmic drug development,” EyeKor CEO Christopher Murphy added. “Our strategic collaboration is an important step for EyeKor to validate the great power of our Excelsior application by assisting Clearside in bringing its ophthalmic therapeutics into the marketplace to benefit patients suffering from serious back-of-the-eye diseases. We look forward to continuing our successful relationship with Clearside.”

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Optical/Ophthalmic, Wall Street Beat Tagged With: Clearside Biomedical, EyeKor

IN CASE YOU MISSED IT

  • Medtronic unveils “MiniMed” as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor
  • Mosanna launches with $80M to support nasal spray for obstructive sleep apnea

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS